Trends in Pricing and Out-of-Pocket Spending on Entecavir Among Commercially Insured Patients, 2014-2018
- PMID: 35061044
- PMCID: PMC8783269
- DOI: 10.1001/jamanetworkopen.2021.44521
Trends in Pricing and Out-of-Pocket Spending on Entecavir Among Commercially Insured Patients, 2014-2018
Erratum in
-
Error in Figure.JAMA Netw Open. 2022 Mar 1;5(3):e225261. doi: 10.1001/jamanetworkopen.2022.5261. JAMA Netw Open. 2022. PMID: 35267039 Free PMC article. No abstract available.
Abstract
This cross-sectional study of health claims from patients with private insurance examines trends in the cost of entecavir prescribed for chronic hepatitis B treatment.
Conflict of interest statement
Figures
References
-
- Medicaid.gov . National Average Drug Acquisition Cost. Updated March 1, 2021. Accessed June 20, 2021. https://www.medicaid.gov/medicaid/prescription-drugs/pharmacy-pricing/in...
-
- Elsevier . Gold Standard Drug Database. Accessed July 2, 2021. https://www.elsevier.com/solutions/drug-database
-
- IQVIA Institute . Medicine Use and Spending in the US, 2019. Published May 9, 2021. Accessed June 1, 2021. https://www.iqvia.com/insights/the-iqvia-institute/reports/medicine-use-...
-
- Bai G, Socal MP, Anderson GF. Policy options to help self-insured employers improve PBM contracting efficiency. Health Affairs Blog. May 29, 2019. Accessed October 2, 2021. https://www.healthaffairs.org/do/10.1377/hblog20190529.43197/full/ - DOI
-
- Langreth R, Ingold D, Gu J. The secret drug pricing system middlemen use to rake in millions. Bloomberg.com. September 11, 2018. Accessed August 20, 2021. https://www.bloomberg.com/graphics/2018-drug-spread-pricing/